BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1077 related articles for article (PubMed ID: 26988947)

  • 1. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
    Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
    J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry.
    Saltijeral A; Pérez de Isla L; Alonso R; Muñiz O; Díaz-Díaz JL; Fuentes F; Mata N; de Andrés R; Díaz-Soto G; Pastor J; Pinilla JM; Zambón D; Pinto X; Badimón L; Mata P;
    Rev Esp Cardiol (Engl Ed); 2017 Jun; 70(6):444-450. PubMed ID: 27913073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
    Vrablik M; Raslová K; Vohnout B; Blaha V; Satny M; Kyselak O; Vaclova M; Urbanek R; Maskova J; Soska V; Freiberger T
    Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target achievement with maximal statin-based lipid-lowering therapy in Korean patients with familial hypercholesterolemia: A study supported by the Korean Society of Lipid and Atherosclerosis.
    Oh J; Lee CJ; Kim DI; Rhee MY; Lee BK; Ahn Y; Cho BR; Woo JT; Hur SH; Jeong JO; Jang Y; Lee SH
    Clin Cardiol; 2017 Dec; 40(12):1291-1296. PubMed ID: 29243274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART).
    Mata N; Alonso R; Badimón L; Padró T; Fuentes F; Muñiz O; Perez-Jiménez F; López-Miranda J; Díaz JL; Vidal JI; Barba A; Piedecausa M; Sanchez JF; Irigoyen L; Guallar E; Ordovas JM; Mata P
    Lipids Health Dis; 2011 Jun; 10():94. PubMed ID: 21663647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.
    Alonso R; Arroyo-Olivares R; Díaz-Díaz JL; Fuentes-Jiménez F; Arrieta F; de Andrés R; Gonzalez-Bustos P; Argueso R; Martin-Ordiales M; Martinez-Faedo C; Illán F; Saenz P; Donate JM; Sanchez Muñoz-Torrero JF; Martinez-Hervas S; Mata P
    Atherosclerosis; 2024 Jun; 393():117516. PubMed ID: 38523000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice.
    Vohnout B; Fábryová Ľ; Klabník A; Kadurová M; Bálinth K; Kozárová M; Bugáňová I; Sirotiaková J; Rašlová K
    Atherosclerosis; 2018 Oct; 277():323-326. PubMed ID: 30270066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
    Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia.
    Menzin J; Aggarwal J; Boatman B; Yu J; Stern K; Harrison DJ; Patel JG
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1270-1276. PubMed ID: 29172973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
    deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
    Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey.
    Krempf M; Simpson RJ; Ramey DR; Brudi P; Giezek H; Tomassini JE; Lee R; Farnier M
    Lipids Health Dis; 2015 May; 14():45. PubMed ID: 25985907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study.
    Pérez de Isla L; Arroyo-Olivares R; Muñiz-Grijalvo O; Diaz-Díaz JL; Zambón D; Fuentes F; Sánchez Muñoz-Torrero JF; Mediavilla JD; González-Estrada A; Miramontes-González JP; de Andrés R; Mauri M; Mosquera D; Cepeda JM; Suárez L; Barba-Romero MÁ; Argüeso R; Álvarez-Baños P; Michán A; Romero-Jiménez MJ; García-Cruces J; Padró T; Alonso R; Mata P
    J Clin Lipidol; 2019; 13(6):989-996. PubMed ID: 31706904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
    Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades.
    Elis A; Zhou R; Stein EA
    Am J Cardiol; 2011 Jul; 108(2):223-6. PubMed ID: 21545982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study.
    Yamashita S; Masuda D; Harada-Shiba M; Arai H; Bujo H; Ishibashi S; Daida H; Koga N; Oikawa S
    J Atheroscler Thromb; 2022 May; 29(5):608-638. PubMed ID: 33980760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
    van Delden XM; Huijgen R; Wolmarans KH; Brice BC; Barron JK; Blom DJ; Marais AD
    Atherosclerosis; 2018 Oct; 277():327-333. PubMed ID: 30270067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
    Miname MH; Santos RD
    Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of severe familial hypercholesterolemia in patients presenting for cardiac catheterization.
    Zafrir B; Shapira C; Lavie G; Halon DA; Flugelman MY
    J Clin Lipidol; 2016; 10(6):1338-1343. PubMed ID: 27919350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
    Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
    Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.